Fusion Pharmaceuticals to Present at the 2020 Wedbush PacGrow Healthcare Virtual Conference

Rhea-AI Summary

Fusion Pharmaceuticals (Nasdaq: FUSN) announced that CEO John Valliant, Ph.D., will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 9:10 AM EDT. The presentation will be available via a live webcast on the company's website, with a replay accessible for 90 days thereafter. Fusion is focused on developing next-generation radiopharmaceuticals using its proprietary Fast-Clear linker technology to target tumors with alpha particle emitting isotopes. Its lead program, FPI-1434, is currently in Phase 1 clinical trials.

News Market Reaction – FUSN

-3.67%

-3.67% Session move

In the trading session that priced this news, FUSN declined 3.67%, reflecting a moderate negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

HAMILTON, Ontario and BOSTON, Aug. 5, 2020 /PRNewswire/ -- Fusion Pharmaceuticals Inc. (Nasdaq: FUSN), a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines, today announced that Chief Executive Officer John Valliant, Ph.D., will present a company overview at the 2020 Wedbush PacGrow Healthcare Virtual Conference on Wednesday, August 12, 2020 at 9:10am EDT.

A live webcast of the event will be available on the "Events and Presentations" page in the "Investors & Media" section of the Company's website at https://ir.fusionpharma.com/events-webcasts. A replay of the webcast will be archived on the Company's website for 90 days following the presentation.  

About Fusion
Fusion Pharmaceuticals is a clinical-stage oncology company focused on developing next-generation radiopharmaceuticals as precision medicines. Employing a proprietary Fast-Clear linker technology, Fusion connects alpha particle emitting isotopes to antibodies and other targeting molecules in order to selectively deliver the alpha emitting payloads to tumors. Fusion's lead program, FPI-1434, is currently in a Phase 1 clinical trial.

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/fusion-pharmaceuticals-to-present-at-the-2020-wedbush-pacgrow-healthcare-virtual-conference-301106527.html

SOURCE Fusion Pharmaceuticals Inc.

FAQ

When will Fusion Pharmaceuticals present at the Wedbush PacGrow Healthcare Virtual Conference?

Fusion Pharmaceuticals will present at the Wedbush PacGrow Healthcare Virtual Conference on August 12, 2020, at 9:10 AM EDT.

How can I watch Fusion Pharmaceuticals' presentation from the conference?

The presentation will be available via live webcast on the 'Events and Presentations' page of Fusion Pharmaceuticals' website.

What is the focus of Fusion Pharmaceuticals?

Fusion Pharmaceuticals focuses on developing next-generation radiopharmaceuticals as precision medicines for oncology.

What is Fusion Pharmaceuticals' lead program?

Fusion Pharmaceuticals' lead program is FPI-1434, which is currently in a Phase 1 clinical trial.

How long will the webcast of the presentation be available after it concludes?

A replay of the webcast will be available for 90 days following the presentation.